Pharming provides background information on recently completed private offering
(Thomson Reuters ONE) -
Leiden, The Netherlands, June 15, 2010. Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announced that it has responded to a
letter from the Dutch Association for Private Investors (Vereniging Van
Effectenbezitters or "VEB") to provide additional information to its
shareholders on the recently completed offering of new shares.
The VEB is a Dutch organization which represents the interest of private
investors. On June 2, 2010, Pharming received a letter from the VEB in which
they requested additional information on the recently completed issue of 100
million new Pharming shares, as announced on May 28, 2010. Pharming's management
has responded to these questions on June 9, 2010. Both letters are in Dutch and
can be found on the website of the VEB at www.veb.net
complete list of questions and answers in Dutch and English can be found on
Pharming's website: www.pharming.com
Relations > Public Reports > Equity Fundraising May 2010.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, ageing diseases, specialty products for surgical indications, and
nutritional products. Pharming's lead product Rhucin® for acute attacks of
Hereditary Angioedema has passed clinical development stage and the Market
Authorization Application is under review with the European Medicines Agency.
Prodarsan® - a product under development by Pharming's subsidiary DNage - is in
early stage clinical development for Cockayne Syndrome and lactoferrin for use
in food products. The advanced technologies of the Company include innovative
platforms for the production of protein therapeutics, technology and processes
for the purification and formulation of these products, as well as technology in
the field of DNA repair (via DNage). Recently the partial spin- out of DNage was
initiated. Additional information is available on the Pharming website,
http://www.pharming.com.
Contact:
Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6
109 299 54
[HUG#1423882]
Press release (PDF): http://hugin.info/132866/R/1423882/372629.pdf
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2010 - 08:00 Uhr
Sprache: Deutsch
News-ID 22414
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming provides background information on recently completed private offering"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
